Morten Uthaug
Clinical Researcher in Psychopharmacology
Data updated
Papers
Trials
Research Footprint
Morten Uthaug appears in 15 tracked papers (2018–2025), most studied alongside Ayahuasca, 5-MeO-DMT and Mescaline, across Anxiety Disorders, Depressive Disorders and Creativity.
Most-cited paper: Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution (213 citations).
Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Kim Kuypers.
Background & Research
Morten Uthaug is a Norwegian clinical researcher whose work sits at the intersection of psychopharmacology, clinical observation and psychedelic epidemiology. He has produced a series of naturalistic studies and analyses examining the psychological effects of a range of entheogens — including 5‑MeO‑DMT vapor from toad secretion, psilocybin in retreat settings, San Pedro (Echinopsis pachanoi) ceremonial use and ayahuasca — and has contributed to population‑level surveys of classic psychedelic use. His research emphasizes real‑world contexts, phenomenological characterisation of altered states, and short‑acting psychedelic compounds as models for fundamental changes in consciousness.
Uthaug’s publications and collaborative projects have also engaged clinical‑pharmacological questions (notably concerning ultra‑short acting tryptamines), ethical considerations in contemporary psychedelic research, and methodological approaches to observational studies and internet‑based epidemiology. He is known for bridging naturalistic fieldwork with controlled pharmacological thinking, contributing to the evidence base on safety, subjective outcomes (for example changes in anxiety, well‑being and mindfulness capacities), and the potential translational applications of rapidly acting psychedelic compounds.
Key Impact
Notable for conducting rigorous naturalistic and epidemiological studies of classic and short‑acting psychedelics, and for advancing pharmacological and phenomenological models of 5‑MeO‑DMT and other entheogens.
Collaboration Network
23 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Morten Uthaug is associated with.
University of Oslo
academicThe Psykedelika-gruppen at the University of Oslo brings together researchers studying the recreational and therapeutic uses of psychedelics. Their projects include surveys on psychedelic use and clinical studies on MDMA for treating depression.
View stakeholder →Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →Maastricht University
academicWhile Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.
View stakeholder →